![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: TFAP2A |
Gene summary for TFAP2A |
![]() |
Gene information | Species | Human | Gene symbol | TFAP2A | Gene ID | 7020 |
Gene name | transcription factor AP-2 alpha | |
Gene Alias | AP-2 | |
Cytomap | 6p24.3 | |
Gene Type | protein-coding | GO ID | GO:0000122 | UniProtAcc | P05549 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
7020 | TFAP2A | AEH-subject5 | Human | Endometrium | AEH | 2.74e-08 | 1.95e-01 | -0.2953 |
7020 | TFAP2A | GSM5276935 | Human | Endometrium | EEC | 3.10e-53 | 6.83e-01 | -0.123 |
7020 | TFAP2A | GSM6177620_NYU_UCEC1_lib1_lib1 | Human | Endometrium | EEC | 1.76e-09 | 4.67e-01 | -0.1869 |
7020 | TFAP2A | GSM6177620_NYU_UCEC1_lib2_lib2 | Human | Endometrium | EEC | 2.68e-10 | 5.32e-01 | -0.1875 |
7020 | TFAP2A | GSM6177620_NYU_UCEC1_lib3_lib3 | Human | Endometrium | EEC | 4.32e-12 | 5.27e-01 | -0.1883 |
7020 | TFAP2A | GSM6177621_NYU_UCEC2_lib1_lib1 | Human | Endometrium | EEC | 1.95e-12 | 4.53e-01 | -0.1934 |
7020 | TFAP2A | GSM6177622_NYU_UCEC3_lib1_lib1 | Human | Endometrium | EEC | 8.72e-09 | 4.18e-01 | -0.1917 |
7020 | TFAP2A | GSM6177622_NYU_UCEC3_lib2_lib2 | Human | Endometrium | EEC | 8.13e-10 | 4.68e-01 | -0.1916 |
7020 | TFAP2A | GSM6177623_NYU_UCEC3_Vis | Human | Endometrium | EEC | 6.66e-10 | 3.14e-01 | -0.1269 |
7020 | TFAP2A | LZE4T | Human | Esophagus | ESCC | 6.76e-07 | 2.70e-01 | 0.0811 |
7020 | TFAP2A | LZE7T | Human | Esophagus | ESCC | 9.76e-06 | 3.37e-01 | 0.0667 |
7020 | TFAP2A | LZE8T | Human | Esophagus | ESCC | 3.18e-06 | 2.86e-01 | 0.067 |
7020 | TFAP2A | LZE20T | Human | Esophagus | ESCC | 4.10e-15 | 4.69e-01 | 0.0662 |
7020 | TFAP2A | LZE22D1 | Human | Esophagus | HGIN | 1.90e-07 | 2.45e-01 | 0.0595 |
7020 | TFAP2A | LZE22T | Human | Esophagus | ESCC | 8.58e-07 | 7.53e-01 | 0.068 |
7020 | TFAP2A | LZE24T | Human | Esophagus | ESCC | 5.71e-19 | 7.27e-01 | 0.0596 |
7020 | TFAP2A | LZE21T | Human | Esophagus | ESCC | 1.42e-02 | 5.79e-01 | 0.0655 |
7020 | TFAP2A | P1T-E | Human | Esophagus | ESCC | 3.95e-22 | 9.82e-01 | 0.0875 |
7020 | TFAP2A | P2T-E | Human | Esophagus | ESCC | 6.18e-90 | 2.07e+00 | 0.1177 |
7020 | TFAP2A | P4T-E | Human | Esophagus | ESCC | 1.63e-24 | 6.25e-01 | 0.1323 |
Page: 1 2 3 4 5 6 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00015038 | Endometrium | AEH | ossification | 78/2100 | 408/18723 | 1.54e-06 | 4.85e-05 | 78 |
GO:00016556 | Endometrium | AEH | urogenital system development | 67/2100 | 338/18723 | 2.30e-06 | 6.76e-05 | 67 |
GO:00720015 | Endometrium | AEH | renal system development | 61/2100 | 302/18723 | 3.43e-06 | 9.24e-05 | 61 |
GO:190121616 | Endometrium | AEH | positive regulation of neuron death | 27/2100 | 97/18723 | 5.35e-06 | 1.36e-04 | 27 |
GO:00018224 | Endometrium | AEH | kidney development | 57/2100 | 293/18723 | 2.25e-05 | 4.35e-04 | 57 |
GO:001003816 | Endometrium | AEH | response to metal ion | 65/2100 | 373/18723 | 2.02e-04 | 2.54e-03 | 65 |
GO:004352510 | Endometrium | AEH | positive regulation of neuron apoptotic process | 16/2100 | 58/18723 | 4.75e-04 | 4.91e-03 | 16 |
GO:00351073 | Endometrium | AEH | appendage morphogenesis | 29/2100 | 138/18723 | 6.06e-04 | 5.94e-03 | 29 |
GO:00351083 | Endometrium | AEH | limb morphogenesis | 29/2100 | 138/18723 | 6.06e-04 | 5.94e-03 | 29 |
GO:00487366 | Endometrium | AEH | appendage development | 33/2100 | 172/18723 | 1.41e-03 | 1.18e-02 | 33 |
GO:00601736 | Endometrium | AEH | limb development | 33/2100 | 172/18723 | 1.41e-03 | 1.18e-02 | 33 |
GO:0010944 | Endometrium | AEH | negative regulation of transcription by competitive promoter binding | 5/2100 | 10/18723 | 2.74e-03 | 1.97e-02 | 5 |
GO:0030326 | Endometrium | AEH | embryonic limb morphogenesis | 23/2100 | 116/18723 | 4.58e-03 | 2.95e-02 | 23 |
GO:0035113 | Endometrium | AEH | embryonic appendage morphogenesis | 23/2100 | 116/18723 | 4.58e-03 | 2.95e-02 | 23 |
GO:0070167 | Endometrium | AEH | regulation of biomineral tissue development | 20/2100 | 97/18723 | 5.00e-03 | 3.14e-02 | 20 |
GO:0035115 | Endometrium | AEH | embryonic forelimb morphogenesis | 9/2100 | 31/18723 | 5.59e-03 | 3.44e-02 | 9 |
GO:190121416 | Endometrium | AEH | regulation of neuron death | 51/2100 | 319/18723 | 5.82e-03 | 3.55e-02 | 51 |
GO:00302822 | Endometrium | AEH | bone mineralization | 23/2100 | 119/18723 | 6.32e-03 | 3.75e-02 | 23 |
GO:0110149 | Endometrium | AEH | regulation of biomineralization | 20/2100 | 99/18723 | 6.34e-03 | 3.76e-02 | 20 |
GO:00163313 | Endometrium | AEH | morphogenesis of embryonic epithelium | 27/2100 | 147/18723 | 6.70e-03 | 3.94e-02 | 27 |
Page: 1 2 3 4 5 6 7 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TFAP2A | SNV | Missense_Mutation | novel | c.829C>T | p.Pro277Ser | p.P277S | P05549 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-FI-A2D5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatinum | PD |
TFAP2A | SNV | Missense_Mutation | c.1214C>A | p.Ala405Asp | p.A405D | P05549 | protein_coding | deleterious(0) | probably_damaging(0.971) | TCGA-FV-A3I1-01 | Liver | liver hepatocellular carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
TFAP2A | SNV | Missense_Mutation | c.37N>T | p.Asp13Tyr | p.D13Y | P05549 | protein_coding | deleterious(0) | benign(0.424) | TCGA-05-4417-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
TFAP2A | SNV | Missense_Mutation | c.36N>C | p.Glu12Asp | p.E12D | P05549 | protein_coding | deleterious(0.02) | possibly_damaging(0.899) | TCGA-05-4417-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
TFAP2A | SNV | Missense_Mutation | c.1048N>T | p.Asp350Tyr | p.D350Y | P05549 | protein_coding | deleterious(0) | probably_damaging(0.98) | TCGA-05-4432-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Chemotherapy | cisplatin | CR | |
TFAP2A | SNV | Missense_Mutation | c.572N>G | p.Ser191Cys | p.S191C | P05549 | protein_coding | tolerated(0.07) | possibly_damaging(0.72) | TCGA-50-6590-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Chemotherapy | paclitaxel | CR | |
TFAP2A | SNV | Missense_Mutation | c.329N>T | p.Thr110Met | p.T110M | P05549 | protein_coding | tolerated(0.12) | benign(0.127) | TCGA-55-8506-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
TFAP2A | SNV | Missense_Mutation | novel | c.604N>A | p.Gly202Ser | p.G202S | P05549 | protein_coding | tolerated(0.24) | probably_damaging(0.994) | TCGA-MN-A4N4-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
TFAP2A | SNV | Missense_Mutation | rs765549775 | c.494N>A | p.Pro165Gln | p.P165Q | P05549 | protein_coding | tolerated(1) | benign(0.003) | TCGA-52-7809-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
TFAP2A | SNV | Missense_Mutation | novel | c.764G>A | p.Arg255Lys | p.R255K | P05549 | protein_coding | deleterious(0.02) | probably_damaging(0.987) | TCGA-85-A50Z-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Chemotherapy | etoposide | PD |
Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
7020 | TFAP2A | TRANSCRIPTION FACTOR | HORMONES | 12704799 | ||
7020 | TFAP2A | TRANSCRIPTION FACTOR | NELFINAVIR | NELFINAVIR | 10996400 | |
7020 | TFAP2A | TRANSCRIPTION FACTOR | INDINAVIR | INDINAVIR | 10996400 | |
7020 | TFAP2A | TRANSCRIPTION FACTOR | TUMOR NECROSIS FACTOR | 11438643 | ||
7020 | TFAP2A | TRANSCRIPTION FACTOR | AMPRENAVIR | AMPRENAVIR | 10996400 | |
7020 | TFAP2A | TRANSCRIPTION FACTOR | TNF-ALPHA | 11438643 |
Page: 1 |